Most Read Articles
5 days ago
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 6 days ago
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 3 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.

General risk algorithms inaccurately predict CV risk in rheumatic patients

01 Jul 2020

Cardiovascular (CV) risk prediction algorithms tend to be inaccurate, frequently underestimating and sometimes overestimating the risk of CV in patients with inflammatory rheumatic diseases, a recent study has shown.

The investigators systematically searched the databases of Embase, Medline, and Cochrane Central for studies that were originally published in English, included clinical CV events as outcomes, examined the predictive properties of at least one CV risk prediction algorithm, and included patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), systemic lupus erythematosus (SLE), psoriatic arthritis (PsA), or psoriasis. By design, only cohort studies following participants for CV events were included.

Of the 146 manuscripts identified, only 11 were included. Eligible studies assessed the predictive performance of the following: Framingham Risk Score, QRISK2, Systematic Coronary Risk Evaluation, Reynolds Risk Score, American College of Cardiology/American Heart Association Pooled Cohort Equations, Expanded Cardiovascular Risk Prediction Score for Rheumatoid Arthritis, and the Italian Progetto CUORE score.

Approaches, such as the use of multipliers, biomarkers, disease-specific variables, or a combination of these to modify or develop an algorithm, were applied to improve the predictive performance of general risk algorithms in RA patients. For instance, multipliers were employed in general risk algorithms in both SLE and PsA patients.

Additionally, efforts to include nontraditional risk factors, disease-related variables, multipliers, and biomarkers in studies of RA and SLE patients did not succeed in significantly improving risk estimate.

“We did not find studies that evaluated models for psoriasis or AS, which further demonstrates a need for research in these populations,” the investigators said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
5 days ago
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 6 days ago
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 3 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.